|
1
|
McGlynn KA, Petrick JL and El-Serag HB:
Epidemiology of hepatocellular carcinoma. Hepatology. 73 (Suppl
1):S4–S13. 2021. View Article : Google Scholar
|
|
2
|
Schütte K, Kipper M, Kahl S, Bornschein J,
Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J and
Malfertheiner P: Clinical characteristics and time trends in
etiology of hepatocellular cancer in Germany. Digestion.
87:147–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet J, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Benson AB, D'Angelica MI, Abbott DE, Anaya
DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, et
al: Hepatobiliary cancers, version 2.2021, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 19:541–565. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogel A and Martinelli E; ESMO Guidelines
Committee. Electronic address, : simpleclinicalguidelines@esmo.org;
ESMO Guidelines Committee: Updated treatment recommendations for
hepatocellular carcinoma (HCC) from the ESMO clinical practice
guidelines. Ann Oncol. 32:801–805. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jost-Brinkmann F, Demir M, Wree A, Luedde
T, Loosen SH, Müller T, Tacke F, Roderburg C and Mohr R:
Atezolizumab plus bevacizumab in unresectable hepatocellular
carcinoma: Results from a German real-world cohort. Aliment
Pharmacol Ther. 57:1313–1325. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jun CH, Yoon JH, Cho E, Shin SS, Cho SB,
Kim HJ, Park CH, Kim HS, Choi SK and Rew JS: Barcelona clinic liver
cancer-stage C hepatocellular carcinoma: A novel approach to
subclassification and treatment. Medicine (Baltimore).
96:e67452017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salem R, Li D, Sommer N, Hernandez S,
Verret W, Ding B and Lencioni R: Characterization of response to
atezolizumab + bevacizumab versus sorafenib for hepatocellular
carcinoma: Results from the IMbrave150 trial. Cancer Med.
10:5437–5447. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs sorafenib for unresectable hepatocellular carcinoma.
J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abou-Alfa GK, Lau G, Kudo M, Chan SL,
Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De
Toni EN, et al: Tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. NEJM Evid. 1:EVIDoa21000702022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bristol Myers Squibb, . Bristol myers
squibb announces checkmate-9DW trial evaluating opdivo (nivolumab)
plus yervoy (ipilimumab) meets primary endpoint of overall survival
for the first-line treatment of advanced hepatocellular carcinoma.
https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-CheckMate-9DW-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Meets-Primary-Endpoint-of-Overall-Survival-for-the-First-Line-Treatment-of-Advanced-Hepatocellular-Carcinoma/default.aspx
|
|
14
|
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X,
Chen Z, Jia W, Jin Y, Guo Y, et al: Camrelizumab plus rivoceranib
versus sorafenib as first-line therapy for unresectable
hepatocellular carcinoma (CARES-310): A randomised, open-label,
international phase 3 study. Lancet. 402:1133–1146. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lencioni R and Llovet J: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fedorov A, Beichel R, Kalpathy-Cramer J,
Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy
F, Sonka M, et al: 3D Slicer as an image computing platform for the
quantitative imaging network. Magn Reson Imaging. 30:1323–1341.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van Griethuysen JJM, Fedorov A, Parmar C,
Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin JC,
Pieper S and Aerts HJWL: Computational radiomics system to decode
the radiographic phenotype. Cancer Res. 77:e104–e107. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vogel A, Rimassa L, Sun HC, Abou-Alfa GK,
El-Khoueiry A, Pinato DJ, Sanchez Alvarez J, Daigl M, Orfanos P,
Leibfried M, et al: Comparative efficacy of atezolizumab plus
bevacizumab and other treatment options for patients with
unresectable hepatocellular carcinoma: A network meta-analysis.
Liver Cancer. 10:240–248. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rimini M, Rimassa L, Ueshima K, Burgio V,
Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, et al:
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in
non-viral unresectable hepatocellular carcinoma: An international
propensity score matching analysis. ESMO Open. 7:1005912022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pfister D, Núñez NG, Pinyol R, Govaere O,
Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, et
al: NASH limits anti-tumour surveillance in immunotherapy-treated
HCC. Nature. 592:450–456. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sangro B, Chan SL, Kelley RK, Lau G, Kudo
M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK,
et al: Four-year overall survival update from the phase III
HIMALAYA study of tremelimumab plus durvalumab in unresectable
hepatocellular carcinoma. Ann Oncol. 35:448–457. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lau G, Sangro B, Crysler OV,
Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio
V, Phuong LTT, Chao T, et al: Temporal patterns of immune-mediated
adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in
the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma
(uHCC). J Clin Oncol. 41 (16 Suppl):S40732023. View Article : Google Scholar
|
|
23
|
Fukushima T, Morimoto M, Kobayashi S, Ueno
M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, et
al: Association between immune-related adverse events and survival
in patients with hepatocellular carcinoma treated with atezolizumab
plus bevacizumab. Oncologist. 28:e526–e533. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eso Y, Takeda H, Taura K, Takai A,
Takahashi K and Seno H: Pretreatment neutrophil-to-lymphocyte ratio
as a predictive marker of response to atezolizumab plus bevacizumab
for hepatocellular carcinoma. Curr Oncol. 28:4157–6416. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scheiner B, Pomej K, Kirstein MM, Hucke F,
Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J,
Fründt TW, et al: Prognosis of patients with hepatocellular
carcinoma treated with immunotherapy-development and validation of
the CRAFITY score. J Hepatol. 76:353–363. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ohama H, Hiraoka A, Tada T, Hirooka M,
Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi
E, et al: Clinical usefulness of newly developed prognostic
predictive score for atezolizumab plus bevacizumab for
hepatocellular carcinoma. Cancer Rep (Hoboken).
7:e20422024.PubMed/NCBI
|
|
27
|
Gairing SJ: Development and validation of
the CABLE score to estimate individual prognosis of patients with
hepatocellular carcinoma treated with 1L atezolizumab and
bevacizumab. Proceedings of the EASL Progress. EASL; Milan: 2024,
https://www.easlcongress.eu/wp-content/uploads/2024/03/List-of-accepted-abstracts-EASL-Congress-2024_new.pdf
|
|
28
|
Hatanaka T, Kakizaki S, Hiraoka A, Tada T,
Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi
E, et al: Development and validation of a modified
albumin-bilirubin grade and α-fetoprotein score (mALF score) for
hepatocellular carcinoma patients receiving atezolizumab and
bevacizumab. Hepatol Int. 17:86–96. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hiraoka A, Kumada T, Tada T, Hirooka M,
Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E,
Fukunishi S, et al: Geriatric nutritional risk index as an
easy-to-use assessment tool for nutritional status in
hepatocellular carcinoma treated with atezolizumab plus
bevacizumab. Hepatol Res. 53:1031–1042. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tada T, Kumada T, Hiraoka A, Kariyama K,
Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi
E, et al: New prognostic system based on inflammation and liver
function predicts prognosis in patients with advanced unresectable
hepatocellular carcinoma treated with atezolizumab plus
bevacizumab: A validation study. Cancer Med. 12:6980–6993. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bera K, Braman N, Gupta A, Velcheti V and
Madabhushi A: Predicting cancer outcomes with radiomics and
artificial intelligence in radiology. Nat Rev Clin Oncol.
19:132–146. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gillies RJ and Schabath MB: Radiomics
improves cancer screening and early detection. Cancer Epidemiol
Biomarkers Prev. 29:2556–2567. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lambin P, Rios-Velazquez E, Leijenaar R,
Carvalho S, Van Stiphout RGPM, Granton P, Zegers CM, Gillies R,
Boellard R, Dekker A and Aerts HJ: Radiomics: Extracting more
information from medical images using advanced feature analysis.
Eur J Cancer. 48:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chong HH, Yang L, Sheng RF, Yu YL, Wu DJ,
Rao SX, Yang C and Zeng MS: Multi-scale and multi-parametric
radiomics of gadoxetate disodium-enhanced MRI predicts
microvascular invasion and outcome in patients with solitary
hepatocellular carcinoma ≤5 cm. Eur Radiol. 31:4824–4838. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gong XQ, Tao YY, Wu Y, Liu N, Yu X, Wang
R, Zheng J, Liu N, Huang XH, Li JD, et al: Progress of MRI
radiomics in hepatocellular carcinoma. Front Oncol. 11:6983732021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Yan C, Weng S, Shi Z, Sun H, Chen J,
Xu X, Ye R and Hong J: Texture analysis of multi-phase MRI images
to detect expression of Ki67 in hepatocellular carcinoma. Clin
Radiol. 74:813.e19–813.e27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xia TY, Zhou ZH, Meng XP, Zha JH, Yu Q,
Wang WL, Song Y, Wang YC, Tang TY, Xu J, et al: Predicting
microvascular invasion in hepatocellular carcinoma using CT-based
radiomics model. Radiology. 307:e2227292023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu X, Zhang HL, Liu QP, Sun SW, Zhang J,
Zhu FP, Yang G, Yan X, Zhang YD and Liu XS: Radiomic analysis of
contrast-enhanced CT predicts microvascular invasion and outcome in
hepatocellular carcinoma. J Hepatol. 70:1133–1144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang R, Wang Y, Li Z, Shi Y, Yu D, Huang
Q, Chen F, Xiao W, Hong Y and Feng Z: Dynamic radiomics based on
contrast-enhanced MRI for predicting microvascular invasion in
hepatocellular carcinoma. BMC Med Imaging. 24:802024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu M, Tan H, Gao F, Hai J, Ning P, Chen J,
Zhu S, Wang M, Dou S and Shi D: Predicting the grade of
hepatocellular carcinoma based on non-contrast-enhanced MRI
radiomics signature. Eur Radiol. 29:2802–2811. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu HF, Wang M, Wang Q, Lu Y, Lu YJ, Sheng
Y, Xing F, Zhang JL, Yu SN and Xing W: Multiparametric MRI-based
intratumoral and peritumoral radiomics for predicting the
pathological differentiation of hepatocellular carcinoma. Insights
Imaging. 15:972024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kong C, Zhao Z, Chen W, Lv X, Shu G, Ye M,
Song J, Ying X, Weng Q, Weng W, et al: Prediction of tumor response
via a pretreatment MRI radiomics-based nomogram in HCC treated with
TACE. Eur Radiol. 31:7500–7511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aoki T, Nishida N, Ueshima K, Morita M,
Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, et al:
Higher enhancement intrahepatic nodules on the hepatobiliary phase
of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of
anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular
carcinoma. Liver Cancer. 10:615–628. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tamura Y, Ono A, Nakahara H, Hayes CN,
Fujii Y, Zhang P, Yamauchi M, Uchikawa S, Teraoka Y, Uchida T, et
al: Association of hepatobiliary phase of gadoxetic-acid-enhanced
MRI imaging with immune microenvironment and response to
atezolizumab plus bevacizumab treatment. Cancers (Basel).
15:42342023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kothari G: Role of radiomics in predicting
immunotherapy response. J Med Imaging Radiat Oncol. 66:575–591.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dercle L, Zhao B, Gönen M, Moskowitz CS,
Firas A, Beylergil V, Connors DE, Yang H, Lu L, Fojo T, et al:
Early readout on overall survival of patients with melanoma treated
with immunotherapy using a novel imaging analysis. JAMA Oncol.
8:385–392. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu H, Bai Y, Xie X, Feng Y, Yang Y and Zhu
Q: RECIST 1.1 versus mRECIST for assessment of tumour response to
molecular targeted therapies and disease outcomes in patients with
hepatocellular carcinoma: A systematic review and meta-analysis.
BMJ Open. 12:e0522942022. View Article : Google Scholar : PubMed/NCBI
|
